Pipeline

Our focus on and deep understanding of the biology and Mechanism of Action of the CD40 Ligand have driven Eledon’s research and development of our lead product candidate tegoprubart. Extensive preclinical and clinical stage research demonstrates that tegoprubart effectively targets the CD40L pathway, which plays a central role in organ rejection. Eledon is currently conducting clinical research on the potential benefits of treatment with tegoprubart in kidney transplantation and xenotransplantation.

The company is also assessing the benefits of targeting the CD40L in patients with autoimmune and neurodegenerative diseases including ALS. Eledon has successfully completed a Phase 2, dose ranging, biomarker study in ALS.

Indications	Preclinical	Phase 1*	Phase 2	Phase 3	Notes
Allotransplantation
Kidney					Phase 2 BESTOW completed Phase 1b & Long-Term Extension trials ongoing
Islet Cell					U. Chicago investigator sponsored trial Received U.S. FDA Orphan Drug Designation
Islet Cell in Patients with Impaired Renal Function					Multi-site investigator sponsored trial
Kidney Tolerance					Mass. General Hospital investigator sponsored trial
Liver					IND-ready
Xenotransplantation
Kidney					eGenesis sponsored Phase 1/2/3 study
Adult Heart					Performed under U.S. FDA Expanded Access Protocol (EAP)
Pediatric Heart
Amyotrophic Lateral Sclerosis (ALS)					Seeking non-equity dilutive financing to advance program to Phase 3

Kidney
Preclinical	Phase 1*	Phase 2	Phase 3	Notes
Phase 2 BESTOW completed Phase 1b & Long-Term Extension trials ongoing
Islet Cell
Preclinical	Phase 1*	Phase 2	Phase 3	Notes
U. Chicago investigator sponsored trial Received U.S. FDA Orphan Drug Designation
Islet Cell in Patients with Impaired Renal Function
Preclinical	Phase 1*	Phase 2	Phase 3	Notes
Multi-site investigator sponsored trial
Kidney Tolerance
Preclinical	Phase 1*	Phase 2	Phase 3	Notes
Mass. General Hospital investigator sponsored trial
Liver
Preclinical	Phase 1*	Phase 2	Phase 3	Notes
IND-ready
Kidney
Preclinical	Phase 1*	Phase 2	Phase 3	Notes
eGenesis sponsored Phase 1/2/3 study
Adult Heart
Preclinical	Phase 1*	Phase 2	Phase 3	Notes
Performed under U.S. FDA Expanded Access Protocol (EAP)
Pediatric Heart
Preclinical	Phase 1*	Phase 2	Phase 3	Notes
Amyotrophic Lateral Sclerosis (ALS)
Preclinical	Phase 1*	Phase 2	Phase 3	Notes
Seeking non-equity dilutive financing to advance program to Phase 3

*Including early human trials
Note: As of October 22, 2025. Development plans and timelines may change, including based on U.S. and global regulatory interactions.